

## 中生北控生物科技股份有限公司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

## Revised form of proxy for the annual general meeting to be held on Thursday, 25 May 2023

I/We (Note 1)

being the registered holder(s) of			res") of RMB1.00 e
the sh	are capital of Biosino Bio-Technology and Science Incorporation (the "Company") HEREBY APPOINT (Note 3)		
aoqiai ournn	g him, the chairman of the meeting as my/our proxy to attend and act for me/us at the annual general meeting (the "Meetin a Road, Science and Technology Industrial Park, Changping District, Beijing, the People's Republic of China (the "PRC") on The nent thereof) for the purposes of considering and, if thought fit, passing the resolutions as set out in the notice and the supplement (and any adjournment thereof) to vote for me/us and in my/our name(s) in respect of the resolutions as hereunder indicated; or if	ursday, 25 May 2023 ntal notice convening	at 10:00 a.m. (and the Meeting and at
	ORDINARY RESOLUTIONS (Note 4)	For (Note 5)	Against (Note 5)
l.	To consider and approve the report of the board of directors of the Company (the "Board") for the year ended 31 December 2022.		
!.	To consider and approve the report of the supervisory committee of the Company for the year ended 31 December 2022.		
3.	To consider and approve the audited consolidated financial statements of the Company and its subsidiaries and the independent auditors' report for the year ended 31 December 2022.		
ļ.	To consider and approve the 2022 annual final financial report and the 2023 financial budget report of the Company.		
5.	To consider and approve the re-appointment of Ernst & Young Hua Ming as the PRC auditors and Ernst & Young as the international auditors of the Company to hold office until the conclusion of the next annual general meeting and to authorise the Board to fix their remuneration.		
5A.	To consider and approve the appointments and re-appointments of the following directors of the Company (the "Director(s)"), and authorise the Board to fix their remuneration and to enter into service contracts with them subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters:—		
	(a) To consider and approve the re-appointment of Mr. Wu Lebin as an executive Director;		
	(b) To consider and approve the re-appointment of Dr. Sun Zhe as a non-executive Director;		
	(c) To consider and approve the re-appointment of Mr. Lu Qi as an independent non-executive Director;		
	(d) To consider and approve the re-appointment of Prof. Shen Jiangang as an independent non-executive Director;		
	(e) To consider and approve the appointment of Mr. Chen Peng as an executive Director;		
	(f) To consider and approve the appointment of Mr. Chen Zhengyong as a non-executive Director;		
	(g) To consider and approve the appointment of Mr. Li Zhonghua as a non-executive Director;		
	(h) To consider and approve the appointment of Dr. Gao Guangxia as a non-executive Director;		
	(i) To consider and approve the appointment of Prof. Shen Zuojun as an independent non-executive Director.		
ίВ.	To consider and approve the appointments and re-appointments of the following supervisors of the Company (the "Supervisor(s)"), and authorise the Board to fix their remuneration and to enter into service contracts with them subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters:—		
	(a) To consider and approve the re-appointment of Dr. Shen Sheng as a Supervisor;		
	(b) To consider and approve the appointment of Mr. Li Jifeng as a Supervisor.		
SPECIAL RESOLUTIONS (Note 4)		For (Note 5)	Against (Note 5)
<b>5</b> .	To give a general mandate to the Board to issue, allot and deal with additional shares not exceeding 20% of the shares of the Company in issue.		
7.	To consider and approve the proposed amendments to the articles of association of the Company.		
ted th	is day of, 2023 Signature(s) (Note 6)		
es:			
P	lease insert the full name(s) and address(es) (as shown in the register of members) in BLOCK CAPITALS.		
P	lease insert the number of shares in the Company registered in your name(s) to which this revised form of proxy relates. If no number is inserted, this revised to the capital of the Company registered in your name(s). Please also strike out the type of shares (Domestic Shares/H Shares) to which the proxy does not recapital of the Company registered in your name(s). Please also strike out the type of shares (Domestic Shares/H Shares) to which the proxy does not recapital of the Company registered in your name(s).	d form of proxy will be d	eemed to relate to all

- Please insert the name and address of the proxy desired. IF NO NAME IS INSERTED, THE CHAIRMAN OF THE MEETING WILL ACT AS YOUR PROXY.
- In fault ext of these resolutions is set out in the notice and supplemental notice of the Meeting issued by the Company on 6 April 2023 and 10 May 2023, respectively.

  Important: If you wish to vote for any resolution, please tick ("V") the relevant box marked "For". If you wish to vote against any resolution, please tick ("V") the relevant box marked "Against". Failure to tick either box of a resolution will entitle your proxy to cast your vote at his/her discretion in respect of that resolution. Your proxy will also be entitled to vote at his/her discretion on any resolution properly put to the Meeting other than those referred to in the notice convening the Meeting.
- This revised form of proxy must be signed by you or your attorney duly authorised in writing or, in the case of a corporation or institution, either under the common seal or under the hand of any director or attorney duly authorized in writing.
- To be valid, this revised form of proxy and, if such revised form of proxy is signed by a person under a power of attorney or other authority on behalf of the appointer, a nominally certified copy of that power of attorney or other authority, must be deposited at the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, and in case of holders of Domestic Shares, to the Company's mailing address at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC, postal code 102200, attention to the secretary to the Board, as soon as possible and in any event not less than 24 hours before the time for holding the Meeting or appointed time of voting or any adjournment thereof.
- A member entitled to attend and vote at the Meeting is entitled to appoint one or more proxies to attend and vote on his behalf. The proxy needs not be a member of the Company but must attend the Meeting in person to represent you
- In the case of the joint holders of any share, only the person whose name appears first in the register of members shall be entitled to attend and exercise all the voting powers attach to such share at the Meeting.
- In the case of the joint holders of any share, only the person whose name appears first in the register of members shall be entitled to attend and exercise all the voting powers attach to such share at the Meeting. Any alteration made to this revised form of proxy must be initialled by the person(s) who sign(s) it.

  If you wish to appoint a proxy to attend and vote at the Meeting on your behalf and if you have not yet returned the first proxy form published on 6 April 2023 (the "First Proxy Form") to the Company, you should complete, sign and return this revised form of proxy which contains the proposals in the revised notice of the Meeting published on 10 May 2023 to Tricor Investor Services Limited at t 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 48 hours before the time appointed for the deeting or any of its adjournments (as the case may be) (the "Closing Time"). In this case, the First Proxy Form should not be submitted to the Company.

  If you wish to appoint a proxy to attend and vote at the Meeting on your behalf, and have already duly completed and submitted the First Proxy Form to the Company, you should note that: (a) if this revised form of proxy is not submitted, the First Proxy Form correctly completed and duly lodged will be treated as a valid proxy form submitted by you. The proxy so appointed shall be required to vote in such manner as he/she may be directed under the First Proxy Form and, in respect of the resolutions; (b) if this revised form of proxy is duly completed and submitted by the revised form of proxy will be entitled to vote at his/her discretion or to abstain from your proxy in the proxy is ally completed and submitted by you; the revised form of proxy will be reated as a valid proxy form submitted by you; and (c) if this revised form of proxy is multiparted by you. This revised form of proxy Form will be invalid and the validity of the First Proxy Form correctly completed and duly submitted by you will not be affected. The proxy appointed by you under